Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Stanislaw R. Burzynski, MD, PhD: novel cancer research and the fight to prove its worth.

Burzynski SR.

Altern Ther Health Med. 2012 May-Jun;18(3):54-61. No abstract available.

PMID:
22875562
[PubMed - indexed for MEDLINE]
2.

Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.

Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.

Integr Cancer Ther. 2006 Mar;5(1):40-7.

PMID:
16484713
[PubMed - indexed for MEDLINE]
3.

Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.

Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V.

Integr Cancer Ther. 2005 Jun;4(2):168-77.

PMID:
15911929
[PubMed - indexed for MEDLINE]
4.

Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.

Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2004;5(6):315-26.

PMID:
15563234
[PubMed - indexed for MEDLINE]
5.

Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme.

Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B.

Integr Cancer Ther. 2004 Sep;3(3):257-61.

PMID:
15312271
[PubMed - indexed for MEDLINE]
6.

Managing social conflict in complementary and alternative medicine research: the case of antineoplastons.

Hammer MR, Jonas WB.

Integr Cancer Ther. 2004 Mar;3(1):59-65.

PMID:
15035877
[PubMed - indexed for MEDLINE]
7.

The present state of antineoplaston research (1).

Burzynski SR.

Integr Cancer Ther. 2004 Mar;3(1):47-58. Review.

PMID:
15035876
[PubMed - indexed for MEDLINE]
8.

Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.

Burzynski SR, Lewy RI, Weaver RA, Axler ML, Janicki TJ, Jurida GF, Paszkowiak JK, Szymkowski BG, Khan MI, Bestak M.

Drugs R D. 2003;4(2):91-101.

PMID:
12718563
[PubMed - indexed for MEDLINE]
9.

Potential utility of antineoplaston A-10 levels in breast cancer.

Badria F, Mabed M, Khafagy W, Abou-Zeid L.

Cancer Lett. 2000 Jul 3;155(1):67-70.

PMID:
10814881
[PubMed - indexed for MEDLINE]
10.

Efficacy of antineoplastons A10 and AS2-1.

Burzynski SR.

Mayo Clin Proc. 1999 Jun;74(6):641-2. No abstract available.

PMID:
10377942
[PubMed - indexed for MEDLINE]
11.

Inhibitory effect of antineoplaston A10 and AS2-1 on human hepatocellular carcinoma.

Tsuda H, Iemura A, Sata M, Uchida M, Yamana K, Hara H.

Kurume Med J. 1996;43(2):137-47.

PMID:
8755117
[PubMed - indexed for MEDLINE]
Free Article
12.

Potential of antineoplastons in diseases of old age.

Burzynski SR.

Drugs Aging. 1995 Sep;7(3):157-67. Review. No abstract available.

PMID:
8535046
[PubMed - indexed for MEDLINE]
13.

Cellular accumulation of antineoplaston AS21 in human hepatoma cells.

Sołtysiak-Pawłuczuk D, Burzyński SR.

Cancer Lett. 1995 Jan 6;88(1):107-12.

PMID:
7850766
[PubMed - indexed for MEDLINE]
14.

Toxicological study on antineoplastons A-10 and AS2-1 in cancer patients.

Tsuda H, Hara H, Eriguchi N, Nishida H, Yoshida H, Kumabe T, Sugita Y.

Kurume Med J. 1995;42(4):241-9.

PMID:
8667595
[PubMed - indexed for MEDLINE]
Free Article
15.

The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors.

Juszkiewicz M, Chodkowska A, Burzynski SR, Mlynarczyk M, Kleinrok Z.

Drugs Exp Clin Res. 1995;21(4):153-6.

PMID:
8529528
[PubMed - indexed for MEDLINE]
16.

The influence of antineoplaston A5 on the central dopaminergic structures.

Juszkiewicz M, Chodkowska A, Burzynski SR, Feldo M, Majewska B, Kleinrok Z.

Drugs Exp Clin Res. 1994;20(4):161-7.

PMID:
7813388
[PubMed - indexed for MEDLINE]
17.

Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1.

Burzynski SR, Kubove E, Burzynski B.

Drugs Exp Clin Res. 1990;16(7):361-9.

PMID:
2152694
[PubMed - indexed for MEDLINE]
18.

Stereochemical modelling studies of the interaction of antineoplaston A10 with DNA.

Hendry LB, Muldoon TG, Burzynski SR, Copland JA, Lehner AF.

Drugs Exp Clin Res. 1987;13 Suppl 1:77-81.

PMID:
3569020
[PubMed - indexed for MEDLINE]
19.

Chemo-surveillance: a novel concept of the natural defence mechanism against cancer.

Liau MC, Szopa M, Burzynski B, Burzynski SR.

Drugs Exp Clin Res. 1987;13 Suppl 1:71-6.

PMID:
3569019
[PubMed - indexed for MEDLINE]
20.

Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy.

Liau MC, Szopa M, Burzynski B, Burzynski SR.

Drugs Exp Clin Res. 1987;13 Suppl 1:61-70.

PMID:
3569018
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk